Pneumonia, Bacterial Clinical Trial
— PROPHETICOfficial title:
Prospective Observational Study of the Risk Factors for Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP)
NCT number | NCT02689531 |
Other study ID # | Pro00068313 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | February 2016 |
Est. completion date | February 2018 |
Verified date | October 2019 |
Source | Duke University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The purpose of this study is to better define the intensive care unit population at highest risk for developing Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP).
Status | Completed |
Enrollment | 7530 |
Est. completion date | February 2018 |
Est. primary completion date | February 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria (Adult arm => 18 years old): - Admission to participating ICU - Hospitalized for >48 hours or admitted <7 days after discharge from an inpatient acute or chronic care facility High-Risk Inclusion (Adult arm => 18 years old): Treated with one or more of the following respiratory modalities for at least 12 hours, either currently or within the prior 7 days: - Invasive mechanical ventilation - Noninvasive ventilation (BiPAP or CPAP for any indication other than obstructive sleep apnea) - High-flow, supplemental oxygen therapy via nasal cannula. Only include systems that using an air/oxygen blender capable of delivering a precise FiO2 level, not just a flow in LPM. - High flow supplemental oxygen therapy delivering at least 50% FiO2 via aerosol facemask or tracheostomy collar (mask). Only include systems using an air/oxygen blender capable of delivering a precise FiO2 level, not just a flow in LPM. - Supplemental oxygen therapy delivered via either partial or non-rebreather face mask Other-ICU Inclusion(Adult arm => 18 years old): All patients who meet ICU and time-frame eligibility criteria, but do not fulfill high-risk criteria, and are receiving an antibiotic for treatment of LRTI or undifferentiated sepsis. Exclusion Criteria(Adult arm => 18 years old): - Age <18 years old - Pregnancy (current) or breastfeeding - Lung cancer or another malignancy metastatic to the lungs (currently receiving treatment) - Patient previously enrolled and treated for suspected HABP or VABP (More than CRF Part 1 was previously completed) - Patient is on comfort measures (e.g. would not receive antibiotics) Inclusion Criteria (Pediatric Arm: < 18 years old) - < 18 years old - Admission to participating ICU or intermediate care unit - Hospitalized for >48 hours or admitted <7 days after discharge from an inpatient acute or chronic care facility Note: Children and infants with pulmonary and cardiac anomalies are eligible to participate. High-Risk Inclusion (Pediatric Arm: < 18 years old) Subjects =120 days old and <18 years old: Currently treated with one or more of the following respiratory modalities for at least 24 hours: - Invasive mechanical ventilation via endotracheal intubation - New initiation of mechanical ventilation, BiPAP or CPAP via tracheostomy - Noninvasive ventilation (BiPAP or CPAP for any indication other than obstructive sleep apnea) - High-flow, supplemental oxygen therapy delivering at least 1.5LMP with 100% FiO2 via nasal cannula when delivered using an air/oxygen blender capable of delivering a precise FiO2 level, not just a flow in LPM - High flow supplemental oxygen therapy delivering at least 50% FiO2 via aerosol facemask or tracheostomy collar (mask) when delivered using an air/oxygen blender capable of delivering a precise FiO2 level, not just a flow in LPM - Supplemental oxygen therapy delivered via either partial or non-rebreather face mask Subjects <120 days old: Currently treated with mechanical ventilation via endotracheal intubation for at least 5 days Standard-Risk Inclusion (Pediatric Arm: < 18 years old) All patients who meet pediatric eligibility criteria, but do not fulfill high-risk criteria, and are receiving an antibiotic for treatment of LRTI or undifferentiated sepsis. Exclusion Criteria (Pediatric Arm: < 18 years old) - Known pregnancy (current) or breastfeeding - Lung cancer or another malignancy metastatic to the lungs (currently receiving treatment) - Patient previously enrolled and treated for suspected HABP or VABP (More than Pediatric CRF Part 1 was previously completed) - Patient is on comfort measures (e.g. would not receive antibiotics) |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Duke University | Clinical Trials Transformation Initiative, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Food and Drug Administration (FDA) |
United States,
Bergin SP, Calvert SB, Farley J, Sun JL, Chiswell K, Dieperink W, Kluytmans J, Lopez-Delgado JC, Leon-Lopez R, Zervos MJ, Kollef MH, Sims M, Kabchi BA, Rubin D, Santiago J, Natarajan M, Tenaerts P, Fowler VG, Holland TL, Bonten MJ, Hullegie SJ. PROPHETIC — View Citation
Bergin SP, Coles A, Calvert SB, Farley J, Powers JH, Zervos MJ, Sims M, Kollef MH, Durkin MJ, Kabchi BA, Donnelly HK, Bardossy AC, Greenshields C, Rubin D, Sun JL, Chiswell K, Santiago J, Gu P, Tenaerts P, Fowler VG Jr, Holland TL. PROPHETIC: Prospective — View Citation
Ericson JE, McGuire J, Michaels MG, Schwarz A, Frenck R, Deville JG, Agarwal S, Bressler AM, Gao J, Spears T, Benjamin DK Jr, Smith PB, Bradley JS; Best Pharmaceuticals for Children Act-Pediatric Trials Network Steering Committee and the Clinical Trials T — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Development of HABP/VABP | Estimate the rate of HABP/VABP diagnosis in ICU subjects who meet the predetermined high-risk criteria. | Through completion of the study, up to 12 months | |
Primary | Eligibility for typical antibacterial clinical trial | Estimate the proportion of ICU subjects diagnosed with HABP/VABP who would be eligible for enrollment in a clinical trial of antibacterial therapy for HABP/VABP per FDA draft guidance on HABP/VABP | Through completion of the study, up to 12 months | |
Secondary | In enrolled subjects, what factors are associated with the development of hospital acquired or ventilator associated pneumonia. | Assess the risk factors, comorbid medical illnesses, and treatment exposures associated with the development of HABP/VABP in ICU subjects at high-risk for developing pneumonia using a logistic regression model with age, sex, height (cm), weight (kg), ICU type, admission source, hospital length of stay at the time of screening (calendar days), ICU length of stay at the time of screening, ICU admission diagnosis, aspiration risk, medical history, type and duration of ventilation, enteral nutrition, medications, and other therapies of interest as factors | Through completion of the study, up to 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03303976 -
Phase I to Test a New Pneumococcal Vaccine
|
Phase 1 | |
Completed |
NCT02459158 -
A Study to Assess the Pharmacokinetic Profile, the Safety, and the Tolerability of ME1100 Inhalation Solution in Patients With Mechanically Ventilated Bacterial Pneumonia
|
Phase 1 | |
Completed |
NCT06113432 -
CPAP Therapy Through a Helmet or a Full Face Mask in Patients With Acute Hypoxemic Respiratory Failure: Cross-over Study
|
N/A | |
Active, not recruiting |
NCT03577964 -
Development of Pneumonia Due to Alveolar Glucose Levels in Systemic Hyperglycemia
|
||
Completed |
NCT04540081 -
Enhancing Electronic Health Systems to Decrease the Burden of Colon Cancer, Lung Cancer, Obesity, Vaccine-Preventable Illness, and LivER Cancer
|
N/A | |
Completed |
NCT00538694 -
Comparative Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia
|
Phase 3 | |
Withdrawn |
NCT02218359 -
Aerosolized Amikacin and Fosfomycin in Mechanically Ventilated Patients With Gram-negative and / or Gram-positive Bacterial Colonization
|
Phase 2 | |
Completed |
NCT01189487 -
The Study of Unasyn-S 12g/Day for Community Acquired Pneumonia (CAP)
|
Phase 3 | |
Completed |
NCT00515034 -
A Safety and Tolerability Study of Doripenem in Patients With Abdominal Infections or Pneumonia
|
Phase 2 | |
Withdrawn |
NCT00245453 -
Outpatient Registry Trial of Respiratory Tract Infections in Adults
|
Phase 4 | |
Completed |
NCT03239665 -
Vaccination Education Through Pharmacists and Senior Centers (VEPSC)
|
N/A | |
Completed |
NCT03034642 -
Modulation of Steroid Immunosuppression by Alveolar Efferocytosis
|
N/A | |
Completed |
NCT04047719 -
Pneumonia in the ImmunoCompromised - Use of the Karius Test for the Detection of Undiagnosed Pathogens
|
||
Completed |
NCT02292498 -
Thermal Imaging to Diagnose and Monitor Suspected Bacterial Infections
|
N/A | |
Completed |
NCT01763008 -
A Study of the Safety and Effectiveness of Doripenem in Filipino Patients With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Complicated Urinary Tract Infections
|
Phase 4 | |
Recruiting |
NCT05976581 -
Using Probability of Community-Acquired Pneumonia to Tailor Antimicrobials Among Inpatients
|
N/A | |
Completed |
NCT03551210 -
Efficacy and Safety of Nemonoxacin vs Levofloxacin in Adult Patients With Community-Acquired Pneumonia
|
Phase 3 | |
Completed |
NCT04158804 -
PROcalcitonin Impact on Antibiotic Reduction, adverSe Events and AVoidable healthcarE Costs (ProSAVE): A RCT
|
N/A | |
Completed |
NCT00805168 -
Inhaled Amikacin Solution (BAY 41-6551) as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia
|
Phase 3 | |
Completed |
NCT02778672 -
Thermal Imaging of the Lung on a Smartphone to Differentiate Bacterial From Non Bacterial Causes of Pneumonia
|
N/A |